Vivek Mohan

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Acute Lymphoblastic Leukemia

Multiple Myeloma

Top Venues

Pediatric blood & cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Vivek Mohan, Sachin Jain, Rahul Naithani
Low-dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe-BIRD) in a child with relapsed/refractory B-cell acute lymphoblastic leukemia with TP53 mutation. Pediatric blood & cancer 71 (9) (2024)
Vivek Mohan, Sachin Jain, Rahul Naithani
Low-dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe-BIRD) in a child with relapsed/refractory B-cell acute lymphoblastic leukemia with TP53 mutation. Pediatric blood & cancer 71 (9) (2024)
Vivek Mohan, Sachin Jain, Rahul Naithani
Low-dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe-BIRD) in a child with relapsed/refractory B-cell acute lymphoblastic leukemia with TP53 mutation. Pediatric blood & cancer 71 (9) (2024)
Vivek Mohan, Sachin Jain, Rahul Naithani
Low-dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe-BIRD) in a child with relapsed/refractory B-cell acute lymphoblastic leukemia with TP53 mutation. Pediatric blood & cancer (2024)